Vertex Pharmaceuticals Inc. — Q3 2010 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2010. Vertex is a biotechnology company developing and commercializing small-molecule medicines. The filing is unaudited; amounts below are in U.S. dollars.
Financial performance and position
| Metric | Q3 2010 | Q3 2009 | Nine months 2010 | Nine months 2009 |
|---|---|---|---|---|
| Revenue | $23.8m | $25.0m | $77.8m | $68.0m |
| Operating loss | $(199.6)m | $(148.2)m | $(529.4)m | $(467.3)m |
| Net loss | $(209.0)m | $(149.6)m | $(574.2)m | $(483.5)m |
| Net loss per share | $(1.04) | $(0.84) | $(2.87) | $(2.86) |
| Operating cash used | Not separately reported for the quarter | $(469.3)m | $(325.3)m |
- Q3 revenue fell 5%; nine-month revenue increased 14%. Revenue was from royalties and collaborations; Vertex reported no product sales.
- Q3 operating expenses rose 29% to $223.4m, including R&D of $170.4m (+29%) and sales, general and administrative expense of $48.9m (+34%). Nine-month expenses rose 13% to $607.3m.
- R&D included $54.0m of commercial-supply investment in the first nine months, versus $14.7m a year earlier. SG&A growth reflected hiring and launch preparation.
- At September 30, cash and cash equivalents were $569.9m and marketable securities were $633.1m, totaling $1.203bn, down $81.9m from year-end 2009. Restricted cash was a further $34.1m. Current assets were $1.226bn and current liabilities $311.6m.
- Operating cash use was partly offset by $391.6m net proceeds from a September convertible-note offering. Capital expenditures were $23.6m for the nine months.
- Debt included $400m principal of 3.35% convertible notes due 2015 and $155m principal of secured notes due 2012. The 2012 notes are subject to potential earlier repayment tied to telaprevir milestones. Total reported liabilities were $1.239bn.
- Gross margin was not clearly presented as a standalone measure; the company’s reported costs primarily reflect R&D and operating expenses.
Material changes and unusual items
- Net loss increased 40% in Q3 and 19% for the nine months, primarily from higher operating costs and non-cash fair-value losses on derivatives associated with 2009 financing transactions.
- Vertex recorded $34.6m of derivative fair-value losses in the first nine months of 2010, reflecting revised estimates of the timing and likelihood of Janssen telaprevir milestones after positive Phase 3 data. The filing says an additional $45.4m of non-cash expenses could arise if the related $250m milestones are earned.
- The September 2010 convertible-note issuance raised $391.6m net. The notes are convertible at approximately $48.83 per share, mature October 2015, and require semiannual interest payments beginning April 2011.
- Collaborative revenue shifted between partners: nine-month Janssen revenue declined to $22.9m from $40.2m, while Mitsubishi Tanabe revenue increased to $32.7m from $7.7m, largely reflecting timing and amortization of prior payments and manufacturing services.
- The $33.2m Kendall Square lease restructuring liability remains subject to estimates that may change materially. No contingent liabilities were accrued at quarter-end.
Outlook, management commentary and risks
- Management expected to complete the U.S. telaprevir NDA submission in Q4 2010 and anticipated possible U.S. sales in 2011, subject to approval and successful commercialization. The filing states no telaprevir product revenue was expected in 2010.
- Management expected final VX-770 registration-program data in the first half of 2011 and said an NDA could be submitted in the second half of 2011 if the data support approval.
- Vertex expected substantial ongoing losses while investing in telaprevir approval and launch, VX-770 and other pipeline programs. It stated that available cash, cash equivalents and marketable securities should fund operations for at least 12 months.
- Telaprevir Phase 3 results included SVR rates of 75% and 69% in the ADVANCE 12-week and 8-week treatment arms, versus 44% for control. In REALIZE, overall SVR was 65% for telaprevir-based arms versus 17% for control. Common adverse events included fatigue, rash, pruritus, nausea, headache and anemia.
- Key risks include FDA or foreign regulatory delays or rejection, manufacturing and supply-chain execution, commercial launch and market acceptance, and competition from Merck’s boceprevir program. Vertex emphasized that approval and 2011 commercialization were not assured.
Important facts for investors to verify
- Progress and timing of the telaprevir NDA review, labeling, manufacturing readiness and any FDA requirements; approval and launch assumptions underpin the outlook.
- VX-770 trial results and whether they support a 2011 filing, alongside developments in the other clinical programs.
- Cash burn relative to the $1.203bn cash-and-securities balance, and the timing of commercial launch spending and any need for additional financing.
- Debt repayment and conversion terms, including milestone-linked 2012 note repayments and the potential dilution from 2015 notes.
- Derivative fair-value charges and milestone proceeds: the $250m Janssen milestones are contingent, and much of the proceeds are committed to debt repayment or a third-party purchaser.
- Whether telaprevir’s adverse-event profile, competition and commercial uptake support management’s anticipated launch and revenue trajectory.